IDH1 mutation targeted therapy for untreated AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests adding a targeted drug (ivosidenib) to standard therapy (azacitidine) with or without another drug (venetoclax) for people with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) or MDS/AML who cannot have strong chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a newly diagnosed blood cancer called AML or MDS/AML that has a specific IDH1 mutation.
- You must be considered unable to receive intensive chemotherapy due to age or health conditions.
- Your white blood cell count must be below 25 x 10⁹/L (can be lowered temporarily with hydroxyurea).
- You must have adequate kidney and liver function (specific lab test results needed).
- You must not have had prior AML treatment (except hydroxyurea or certain MDS treatments).
- You must agree to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
This trial tests whether adding the targeted therapy olutasidenib to the chemotherapy drug azacitidine can help people with a certain type of AML (one with an IDH1 mutation) who have already had some treatment but still have the disease. The goal is to see if this combination can lead to a longer remission.
This Phase 2 trial tests different ways of using medicines that target IDH mutations (IDH-targeted treatment) plus venetoclax in people newly diagnosed with IDH-mutated AML. It’s designed for patients who cannot safely receive intensive induction chemotherapy, to see which approach works best and is tolerable.
This trial tests a combination of three targeted drugs for people with a specific type of AML that has an IDH1 mutation. The goal is to see if the combination helps control the leukemia and if continuing with just ivosidenib can keep it in remission.
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
This trial tests a combination of olutasidenib, venetoclax, and azacitidine for people with newly diagnosed acute myeloid leukemia (AML) that has an IDH1 mutation. It is for patients who are healthy enough for intensive chemotherapy. The goal is to see if this drug combination works better than standard treatment.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.